S
Stewart C. Pearson
Researcher at GlaxoSmithKline
Publications - 22
Citations - 1016
Stewart C. Pearson is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Antibacterial agent & Nucleic acid. The author has an hindex of 9, co-authored 22 publications receiving 957 citations. Previous affiliations of Stewart C. Pearson include University of Liège.
Papers
More filters
Journal ArticleDOI
Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
Nestor O. Concha,Cheryl A. Janson,Pam Rowling,Stewart C. Pearson,Christy A. Cheever,Brian Peter SmithKline Beecham Pharm Clarke,Ceri Lewis,Moreno Galleni,Jean-Marie Frere,David J. Payne,Bateson John Hargreaves,Sherin S. Abdel-Meguid +11 more
TL;DR: A unique mode of binding of the mercaptocarboxylate inhibitor in the enzyme active site provides a binding model for metallo beta-lactamase inhibition with utility for future drug design.
Journal ArticleDOI
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
David J. Payne,William H. Miller,Valerie Berry,John Brosky,Walter J. Burgess,Emile Chen,Walter E. DeWolf,Andrew P. Fosberry,Rebecca Claire Greenwood,Martha S. Head,Dirk A. Heerding,Cheryl A. Janson,Deborah Dee Jaworski,Paul M. Keller,Manley Peter J,Terrance D. Moore,Kenneth A. Newlander,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Courtney Slater-Radosti,Kevin L. Salyers,Mark A. Seefeld,Martin G. Smyth,Dennis T. Takata,Irene N. Uzinskas,Kalindi Vaidya,Nicola G. Wallis,Scott B. Winram,Catherine C.K. Yuan,William F. Huffman +31 more
TL;DR: Results show that compound 4 is representative of a new, totally synthetic series of antibacterial agents that has the potential to provide novel alternatives for the treatment of S. aureus infections that are resistant to the present armory of antibiotics.
Journal ArticleDOI
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Mark A. Seefeld,William H. Miller,Kenneth A. Newlander,Walter J. Burgess,Walter E. DeWolf,Patricia A. Elkins,Martha S. Head,Dalia R. Jakas,Cheryl A. Janson,Paul M. Keller,Manley Peter J,Terrance D. Moore,David J. Payne,Stewart C. Pearson,Brian J. Polizzi,Xiayang Qiu,Stephen Rittenhouse,Irene N. Uzinskas,Nicola G. Wallis,William F. Huffman +19 more
TL;DR: The hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents is supported, with a new series of inhibitors developed with greatly increased potency against FabI-containing organisms.
Journal ArticleDOI
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
William H. Miller,Mark A. Seefeld,Kenneth A. Newlander,Irene N. Uzinskas,Walter J. Burgess,Dirk A. Heerding,Catherine C.K. Yuan,Martha S. Head,David J. Payne,Stephen Rittenhouse,Terrance D. Moore,Stewart C. Pearson,Valerie Berry,Walter E. DeWolf,Paul M. Keller,Brian J. Polizzi,Xiayang Qiu,Cheryl A. Janson,William F. Huffman +18 more
TL;DR: Results support FabI as a valid antibacterial target and demonstrate the potential of small-molecule FabI inhibitors for the treatment of bacterial infections.
Journal ArticleDOI
Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-β-Lactamases
David J. Payne,Juan A. Hueso-Rodríguez,Helen F. Boyd,Nestor O. Concha,Cheryl A. Janson,Martin Gilpin,John H. Bateson,Christy Cheever,Niconovich Nancy,Stewart C. Pearson,Stephen Rittenhouse,David G. Tew,E. Diez,Paloma Perez,Jesús Ángel de la Fuente,Michael Rees,Alfonso Rivera-Sagredo +16 more
TL;DR: This series of metallo-β-lactamase inhibitors exhibit the most promising antibacterial synergy activity so far observed against organisms producing meetallo- β- lactamases.